0000950170-23-024568.txt : 20230526 0000950170-23-024568.hdr.sgml : 20230526 20230526172902 ACCESSION NUMBER: 0000950170-23-024568 CONFORMED SUBMISSION TYPE: 4/A PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20230505 FILED AS OF DATE: 20230526 DATE AS OF CHANGE: 20230526 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: ARMEN GARO H CENTRAL INDEX KEY: 0000935679 FILING VALUES: FORM TYPE: 4/A SEC ACT: 1934 Act SEC FILE NUMBER: 001-40908 FILM NUMBER: 23970446 MAIL ADDRESS: STREET 1: 3 FORBES ROAD CITY: LEXINGTON STATE: MA ZIP: 02421 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: MiNK Therapeutics, Inc. CENTRAL INDEX KEY: 0001840229 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 149 FIFTH AVENUE STREET 2: SUITE 500 CITY: NEW YORK STATE: NY ZIP: 10010 BUSINESS PHONE: 212-994-8250 MAIL ADDRESS: STREET 1: 149 FIFTH AVENUE STREET 2: SUITE 500 CITY: NEW YORK STATE: NY ZIP: 10010 FORMER COMPANY: FORMER CONFORMED NAME: AgenTus Therapeutics, Inc. DATE OF NAME CHANGE: 20210112 4/A 1 ownership.xml 4/A X0407 4/A 2023-05-05 2023-05-05 0001840229 MiNK Therapeutics, Inc. INKT 0000935679 ARMEN GARO H 149 FIFTH AVENUE, SUITE 500 NEW YORK NY 10010 true false false false false Common Stock 1966400 D On May 5, 2023, Garo Armen, the CEO and Chairman of Agenus, disclosed a transaction involving 100,000 MiNK Therapeutics shares. He agreed to sell these shares to Agenus at his original purchase price, which was lower than the market price at the time of the proposed sale. This action was taken to prevent any perception of Dr. Armen benefitting from low-cost purchases while Agenus was buying at higher prices in separate transactions. However, due to the shares being in Dr. Armen's IRA account, their transfer was prohibited, leading the broker to reverse the sale and decline Agenus' payment. Consequently, the MiNK Therapeutics shares were returned to Dr. Armen, and the sale price was given back to Agenus. This amendment accounts for the changes in Dr. Armen's share ownership following the reversal of this transaction. By: /s/ Christine Klaskin, Attorney-in-Fact for Garo H. Armen 2023-05-26